Evaluation of the efficacy and safety of intravitreal bimonthly injection of aflibercept for age-related macular degeneration

Evaluation of the efficacy and safety of intravitreal bimonthly injection of aflibercept for age-related macular degeneration - Bimonthly injection of aflibercept for age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010312

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

Duration:12 months Quantity:aflibercept 2mg Bimonthly injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with active age-related macular degeneration

Exclusion criteria

Exclusion criteria: Patients with not active age-related macular degeneration, severe glaucoma, inflammation disease, diabetic retinopathy

Design outcomes

Primary

Measure	Time frame
Variation on a logarithm of the minimum angle of resolution 12 months after the first intravitreal injection	—

Secondary

Measure	Time frame
Variation on a central retinal thickness and the number of injection of medicine 12 months after the first intravitreal injection	—

Countries

Japan

Contacts

Public ContactTomoko Sawada

Shiga University of Medical Science Department of Ophthalmology

tsawada@belle.shiga-med.ac.jp0775462276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026